Hookipa Pharma (NASDAQ:HOOK) PT Lowered to $5.00

Hookipa Pharma (NASDAQ:HOOKGet Free Report) had its target price lowered by equities researchers at Royal Bank of Canada from $6.00 to $5.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock.

Hookipa Pharma Price Performance

Shares of NASDAQ:HOOK opened at $0.62 on Tuesday. The business has a 50-day moving average of $0.68 and a two-hundred day moving average of $0.64. The stock has a market capitalization of $52.14 million, a P/E ratio of -0.75 and a beta of 0.98. Hookipa Pharma has a fifty-two week low of $0.41 and a fifty-two week high of $2.05.

Hookipa Pharma (NASDAQ:HOOKGet Free Report) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $6.87 million during the quarter, compared to analyst estimates of $3.39 million. Hookipa Pharma had a negative return on equity of 70.24% and a negative net margin of 336.12%. As a group, research analysts expect that Hookipa Pharma will post -0.87 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in shares of Hookipa Pharma in the second quarter valued at $47,000. Mirabella Financial Services LLP bought a new stake in shares of Hookipa Pharma during the first quarter valued at approximately $82,000. Two Sigma Investments LP acquired a new stake in shares of Hookipa Pharma in the third quarter valued at approximately $51,000. Vontobel Holding Ltd. acquired a new stake in Hookipa Pharma in the second quarter worth about $40,000. Finally, Jane Street Group LLC acquired a new position in Hookipa Pharma in the fourth quarter valued at approximately $43,000. 83.02% of the stock is owned by institutional investors.

About Hookipa Pharma

(Get Free Report)

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

Featured Stories

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.